Upgrade to SI Premium - Free Trial

Needham & Company Reiterates Buy Rating on Sage Therapeutics (SAGE), Analysts Expects no Impact on Stock From the Recent Earning Readout

February 24, 2022 7:26 AM
Needham & Company analyst Ami Fadia reiterated a Buy rating and $85.00 price target on Sage Therapeutics (NASDAQ: SAGE) following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles